PPARG and Parkinson disease: These effects are predominantly considered to result from the anti-inflammatory actions mediated by PPARγ activation (Dehmer et al., 2004; Schintu et al., 2009; Kiaei et al., 2005), indeed both rosiglitazone and pioglitazone have been shown to reduce microgliosis and astrogliosis in the MPTP mouse model of PD (Dehmer et al., 2004; Breidert et al., 2002; Schintu et al., 2009).